Flotufolastat (18F), sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.[1] The active ingredient is flotufolastat (18F).[1]

Flotufolastat (18F) was approved for medical use in the United States in May 2023.[1][2]

Medical uses

Flotufolastat (18F) is indicated for positron emission tomography of prostate-specific membrane antigen positive lesions in men with prostate cancer.[1][3]

References

  1. ^ a b c d e "Posluma- flotufolastat f-18 injection". DailyMed. 2 June 2023. Retrieved 25 June 2023.
  2. ^ "U.S. FDA Approves Blue Earth Diagnostics' Posluma (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer" (Press release). Blue Earth Therapeutics. 30 May 2023. Retrieved 25 June 2023 – via Business Wire.
  3. ^ Heo YA (September 2023). "Flotufolastat F 18: Diagnostic First Approval". Molecular Diagnosis & Therapy. 27 (5): 631–636. doi:10.1007/s40291-023-00665-y. PMID 37439946. S2CID 259843992.
  • Clinical trial number NCT04186819 for "Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)" at ClinicalTrials.gov
  • Clinical trial number NCT04186845 for "Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)" at ClinicalTrials.gov


Allikas: http://en.wikipedia.org/wiki/Flotufolastat_F-18
No tags for this post.